Suppr超能文献

颅底脊索瘤患者生活质量的决定因素。

Determinants of quality of life in patients with skull base chordoma.

机构信息

Division of Neurosurgery, Department of Surgery, St. Michael's Hospital, University of Toronto; and.

出版信息

J Neurosurg. 2014 Feb;120(2):528-37. doi: 10.3171/2013.9.JNS13671. Epub 2013 Oct 25.

Abstract

OBJECT

Skull base chordomas can be managed by surgical intervention and adjuvant radiotherapy. As survival for this disease increases, identification of determinants of quality of life becomes an important focus for guiding comprehensive patient care. In this study the authors sought to measure functional outcome and quality of life in patients with skull base chordomas and to identify determinants of quality of life in these patients.

METHODS

The authors carried out an internet-based cross-sectional survey, collecting detailed data for 83 individual patients. Demographic and clinical variables were evaluated. Functional outcomes were determined by Karnofsky Performance Scale (KPS) and Glasgow Outcome Scale Extended (GOSE), quality of life was measured using the 36-Item Short Form Health Survey (SF-36), and depression was assessed using Patient Health Questions-9 (PHQ-9) instrument. Caregiver burden was assessed using the Zarit Burden Interview (ZBI). Univariate and multivariate analysis was performed to identify determinants of the physical and mental components of the SF-36.

RESULTS

Patients with skull base chordomas who have undergone surgery and/or radiation treatment had a median KPS score of 90 (range 10-100, IQR 10) and a median GOSE score of 8 (range 2-8, IQR 3). The mean SF-36 Physical Component Summary score (± SD) was 43.6 ± 11.8, the mean Mental Component Summary score was 44.2 ± 12.6, and both were significantly lower than norms for the general US population (p < 0.001). The median PHQ-9 score was 5 (range 0-27, IQR 8). A PHQ-9 score of 10 or greater, indicating moderate to severe depression, was observed in 29% of patients. The median ZBI score was 12 (range 0-27, IQR 11), indicating a low burden. Neurological deficit, use of pain medication, and requirement for corticosteroids were found to be associated with worse SF-36 Physical Component Summary score, while higher levels of depression (higher PHQ-9 score) correlated with worse SF-36 Mental Component Summary score.

CONCLUSIONS

Patients with skull base chordomas have a lower quality of life than the general US population. The most significant determinants of quality of life in the posttreatment phase in this patient population were neurological deficits (sensory deficit and bowel/bladder dysfunction), pain medication use, corticosteroid use, and levels of depression as scored by PHQ-9.

摘要

目的

颅底脊索瘤可通过手术干预和辅助放疗进行治疗。随着这种疾病患者生存率的提高,确定生活质量的决定因素成为指导全面患者护理的一个重要焦点。在这项研究中,作者旨在测量颅底脊索瘤患者的功能结果和生活质量,并确定这些患者生活质量的决定因素。

方法

作者进行了一项基于互联网的横断面调查,共收集了 83 名患者的详细数据。评估了人口统计学和临床变量。功能结果通过 Karnofsky 表现量表(KPS)和格拉斯哥结局量表扩展版(GOSE)确定,生活质量使用 36 项简短健康调查问卷(SF-36)进行测量,抑郁使用患者健康问卷-9(PHQ-9)进行评估。使用 Zarit 负担量表(ZBI)评估照顾者负担。进行单变量和多变量分析以确定 SF-36 的身体和心理成分的决定因素。

结果

接受手术和/或放疗的颅底脊索瘤患者的中位 KPS 评分为 90(范围 10-100,IQR 10),中位 GOSE 评分为 8(范围 2-8,IQR 3)。SF-36 生理成分综合评分的平均值(±SD)为 43.6±11.8,心理成分综合评分的平均值为 44.2±12.6,均显著低于美国普通人群的正常值(p<0.001)。PHQ-9 的中位数为 5(范围 0-27,IQR 8)。29%的患者 PHQ-9 评分≥10,表明存在中重度抑郁。ZBI 的中位数为 12(范围 0-27,IQR 11),表明负担较低。作者发现,神经功能缺损、使用止痛药物和需要使用皮质类固醇与 SF-36 生理成分综合评分较差相关,而较高水平的抑郁(较高的 PHQ-9 评分)与 SF-36 心理成分综合评分较差相关。

结论

颅底脊索瘤患者的生活质量低于美国普通人群。在该患者人群的治疗后阶段,生活质量的最重要决定因素是神经功能缺损(感觉缺损和肠/膀胱功能障碍)、止痛药物使用、皮质类固醇使用以及 PHQ-9 评分的抑郁程度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验